Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Isofol Medical AB ( (SE:ISOFOL) ) has shared an update.
Isofol Medical has expanded its global exclusive license for its lead candidate arfolitixorin to cover development and commercialization in autism spectrum disorder, specifically targeting patients with cerebral folate deficiency, a subgroup believed to benefit from folate-based therapies. The company has also filed a related patent application and initiated an exploratory pre-clinical study, positioning itself to capture emerging opportunities in autism while maintaining its primary strategic focus on advancing arfolitixorin for colorectal cancer, where it sees a significant unmet medical need and potential treatment gap in oncology care.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.64 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
More about Isofol Medical AB
Isofol Medical AB is a Swedish biopharmaceutical company focused on improving treatment and quality of life for patients with severe cancers, particularly solid tumors. Its lead drug candidate, arfolitixorin, is a next-generation folate-based therapy intended to enhance the efficacy of first-line standard treatments such as those used in colorectal cancer, and is currently being evaluated in a phase Ib/II study with an optimized dosing regimen.
Average Trading Volume: 1,514,278
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK185.1M
For an in-depth examination of ISOFOL stock, go to TipRanks’ Overview page.